Fatty‐acid amide hydrolase inhibition mitigates Alzheimer's disease progression in mouse models of amyloidosis
The FEBS Journal · 2025-08 · 292 (16) · 4160-4182
DOI: 10.1111/febs.17403 ↗At a glance
Journal article in The FEBS Journal, published online on 2025-01-16. Written by Sergio Oddi and 12 co-authors. Institution: Department of Veterinary Medicine, University of Teramo, Italy. Major MEDLINE topics: Alzheimer Disease, Amidohydrolases, Amyloidosis. Cited 14 times so far (Crossref); 71 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Ministero dell'Università e della Ricerca.
Topics: Demenz
Abstract (original language)
The endocannabinoid N ‐arachidonoylethanolamine (AEA) is a pro‐homeostatic bioactive lipid known for its anti‐inflammatory, anti‐oxidative, immunomodulatory, and neuroprotective properties, which may contrast/mitigate Alzheimer's disease (AD) pathology. This study explores the therapeutic potential of targeting fatty acid amide hydrolase (FAAH), the major enzyme degrading AEA, in mouse models of amyloidosis (APP/PS1 and Tg2576). Enhancing AEA signaling by genetic deletion of FAAH delayed cognitive deficits in APP/PS1 mice and improved cognitive symptoms in 12‐month‐old AD‐like mice. Chronic pharmacological FAAH inhibition fully reverted neurocognitive decline, attenuated neuroinflammation, and promoted neuroprotective mechanisms in Tg2576 mice. Additionally, pharmacological FAAH inhibition robustly suppressed β‐amyloid production and accumulation, associated with decreased expression of β‐site amyloid precursor protein cleaving enzyme 1 (BACE1), possibly through a cannabinoid receptor 1‐dependent epigenetic mechanism. These findings improve our understanding of AEA signaling in AD pathogenesis and provide proof of concept that selective targeting of FAAH activity could be a promising therapeutic strategy against AD.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Veterinary Medicine, University of Teramo, Italy.
- European Center for Brain Research/Institute for Research and Health Care (IRCCS) Santa Lucia Foundation, Rome, Italy.
- Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Italy.
- Department of Pharmacy - Pharmaceutical Sciences, University of Bari "Aldo Moro", Bari, Italy.
- Department of Medicine, Campus Bio-Medico University of Rome, Italy.
- Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy.
ORCID profiles: Sergio Oddi, Francesca Ciaramellano
Funding
- Ministero dell'Università e della Ricerca
Cite
APA
Oddi, S., Scipioni, L., Totaro, A., Giacovazzo, G., Ciaramellano, F., Tortolani, D., Leuti, A., Businaro, R., Armeli, F., Bilkei-Gorzo, A., Coccurello, R., Zimmer, A., & Maccarrone, M. (2025). Fatty‐acid amide hydrolase inhibition mitigates Alzheimer's disease progression in mouse models of amyloidosis. The FEBS Journal, 292(16), 4160-4182. https://doi.org/10.1111/febs.17403
Vancouver
Oddi S, Scipioni L, Totaro A, Giacovazzo G, Ciaramellano F, Tortolani D, et al. Fatty‐acid amide hydrolase inhibition mitigates Alzheimer's disease progression in mouse models of amyloidosis. The FEBS Journal. 2025;292(16):4160-4182. doi:10.1111/febs.17403
BibTeX
@article{Oddi2025,
author = {Oddi, Sergio and Scipioni, Lucia and Totaro, Antonio and Giacovazzo, Giacomo and Ciaramellano, Francesca and Tortolani, Daniel and Leuti, Alessandro and Businaro, Rita and Armeli, Federica and Bilkei-Gorzo, Andras and Coccurello, Roberto and Zimmer, Andreas and Maccarrone, Mauro},
title = {Fatty‐acid amide hydrolase inhibition mitigates Alzheimer's disease progression in mouse models of amyloidosis},
journal = {The FEBS Journal},
year = {2025},
volume = {292},
number = {16},
pages = {4160--4182},
doi = {10.1111/febs.17403}
}
EUVIMED